Molecular ablation of transforming growth factor β signaling pathways by tyrosine kinase inhibition: The coming of a promising new era in the treatment of tissue fibrosis
Open Access
- 30 July 2008
- journal article
- editorial
- Published by Wiley in Arthritis & Rheumatism
- Vol. 58 (8) , 2219-2224
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Imatinib mesylate treatment of nephrogenic systemic fibrosisArthritis & Rheumatism, 2008
- Smad1 pathway is activated in systemic sclerosis fibroblasts and is targeted by imatinib mesylateArthritis & Rheumatism, 2008
- Is imatinib mesylate a promising drug in systemic sclerosis?Arthritis & Rheumatism, 2008
- TGF‐β signaling: A tale of two responsesJournal of Cellular Biochemistry, 2007
- Systemic sclerosis: a prototypic multisystem fibrotic disorderJournal of Clinical Investigation, 2007
- Transforming Growth Factor β Activation of c-Abl Is Independent of Receptor Internalization and Regulated by Phosphatidylinositol 3-Kinase and PAK2 in Mesenchymal CulturesJournal of Biological Chemistry, 2006
- The logic of TGFβ signalingFEBS Letters, 2006
- Renal fibrosis: New insights into the pathogenesis and therapeuticsKidney International, 2006
- Smad-dependent and Smad-independent pathways in TGF-β family signallingNature, 2003
- Role of Transforming Growth Factor β in Human DiseaseNew England Journal of Medicine, 2000